The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.
UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer
UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.
Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
Sasanlimab Plus BCG Boosts Event-Free Survival in High-Risk NMIBC
Emerging Immunotherapy Approaches For Urothelial Cancer
Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.
FDA Grants Priority Review to Durvalumab/Chemo in Bladder Cancer
The FDA set a Prescription Drug User Fee act date in the second quarter of 2025 for durvalumab plus chemotherapy in muscle-invasive bladder cancer.
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma
“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD